$ONCS I'm expecting the November gap down to be filled very shortly, perhaps as early as Friday or early next week, depending on what comes out of Friday's conference call.
If data was not moving in the right direction Merck would not agree to yet another trial , this time for cervical cancer. That will be 4 trials going soon if you include Head and Neck cancer. When trials are not going well Merck abandons them. Oncosec has the potential to go on a monster run with promising data in the hardest to treat patient populations....they will get approvals.